Skip to main content
. Author manuscript; available in PMC: 2007 Sep 17.
Published in final edited form as: Pharmacogenet Genomics. 2006 Dec;16(12):891–899. doi: 10.1097/01.fpc.0000236324.96056.16

Table 3.

Hazard rate ratio between T-786C and E298D polymorphisms and risk of incident CHD or stroke

Caucasian African-American
Polymorphism HRR 95% CI P-value HRR 95% CI P-value
CHD
E298D G/T + T/T versus G/G G/T + T/T versus G/G
 Model 1a 0.94 0.75−1.17 P=0.586 0.87 0.57−1.34 P=0.526
 Model 2b 1.03 0.80−1.33 P=0.819 0.66 0.40−1.09 P=0.105
T-786C T/C + C/C versus T/T T/C + C/C versus T/T
 Model 1a 1.13 0.90−1.42 P=0.210 0.80 0.52−1.20 P=0.279
 Model 2b 1.24 0.96−1.62 P=0.106 0.83 0.53−1.31 P=0.421
Stroke
E298D G/T + T/T versus G/G G/T + T/T versus G/G
 Model 1a 0.94 0.65−1.36 P=0.742 1.50 0.89−2.53 P=0.133
 Model 2c 0.97 0.65−1.44 P=0.884 1.35 0.76−2.41 P=0.311
T-786C T/C + C/C versus T/T T/C + C/C versus T/T
 Model 1a 1.06 0.72−1.55 P=0.783 1.70 1.05−2.75 P=0.032
 Model 2c 1.09 0.73−1.64 P=0.665 1.63 0.93−2.88 P=0.090

CHD, coronary heart disease; HRR, hazard rate ratio; CI, confidence interval.

a

Adjusted for age, sex, and study center.

b

Adjusted for age, sex, study center, current smoker, diabetes, hypertension, HDL cholesterol, total cholesterol, and body mass index.

c

Adjusted for age, sex, study center, current smoker, diabetes, and hypertension.